Radium-223 causes a stir at EMCC
Thursday 29 September 2011
Research on the investigational agent radium-223 chloride caused a stir at the European Multidisciplinary Cancer Congress (EMCC). Preliminary results showed that the agent cut the risk of dying during follow-up by 30% among men with castration-resistant prostate cancer and bone metastases. Dr Chris Parker, lead author of the research, said: ‘In my opinion, radium-223, which has a completely novel mechanism of action, is likely to become a new standard treatment for this disease.’
>> http://www.oncologystat.com/news/Radium-223_Could_Alter_Metastatic_Prostate_Cancer_Management_US.html
European Oncology Nursing SocietyAvenue E. Mounier 83
B-1200 Brussels
Belgium
Tel: +32 (0)2 779 9923
Fax: +32 (0)2 779 9937
eons.secretariat@cancernurse.eu